IL33 and triple-A syndrome: Exogenous IL-33 (daily intraperitoneal administration of recombinant IL-33 or transgenic IL-33 expression) protected mice from the effects of AAA formation by enhancing ST2-dependent aortic and systemic regulatory T-cell amplification (Li J. et al., 2019).